Addiction news and addiction widget

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced positive results in its Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia(TM) program. Convivia(TM) is Raptor's proprietary oral formulation of 4-MP designed to reduce systemic acetaldehyde exposure and related symptoms in ALDH2 deficient persons following alcohol consumption.

New research from Swansea University in the U.K. suggests that frequent use of ecstasy causes problems with memory.

Smoking in the U.S. has increased due to stresses associated with rising unemployment rates, weakening retirement funds, and an overall, slowing economy, according to a new survey.

Obesity and smoking are each risk factors for early death, but new research suggests that together they pose a profound mortality risk.

Lengthier treatment stays for addiction have better rates of success, research shows, and some traditional 28-day programs have extended their programs to up to 90 days.